drugset

drugset / Trial / NCT07214740

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

NCT07214740 ↗

Phase 3 Completed 44 enrolled Apellis Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)

Timeline

Start: 2025-10-24
Primary completion: 2025-12-12
Completion: 2025-12-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegcetacoplan	Peptide	15 mg	Intravitreal

Indications